Scinai Licenses Universal Flu Vaccine Candidate VAA437
Ticker: SCNI · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: licensing-agreement, drug-development, vaccine
TL;DR
Scinai just licensed its universal flu vaccine (VAA437) globally to a US company. Potential future cash!
AI Summary
On September 26, 2024, Scinai Immunotherapeutics Ltd. entered into a license agreement with an unaffiliated U.S. private company. This agreement grants the Licensee exclusive global rights to Scinai's VAA437 (a universal flu vaccine candidate).
Why It Matters
This licensing deal could provide Scinai with future revenue streams and advance the development of its universal flu vaccine candidate.
Risk Assessment
Risk Level: medium — The filing details a licensing agreement, but the financial terms and potential success of the licensed product are not yet fully disclosed, introducing uncertainty.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant and licensor
- VAA437 (drug_candidate) — Licensed universal flu vaccine candidate
- September 26, 2024 (date) — Date of license agreement
FAQ
What are the specific financial terms of the license agreement?
The filing does not disclose the specific financial terms of the license agreement, only that exclusive global rights were granted.
Who is the unaffiliated U.S. private company that entered into the agreement?
The filing refers to the counterparty as an 'unaffiliated U.S. private company' and does not disclose its name.
What is the current development stage of VAA437?
The filing identifies VAA437 as a 'universal flu vaccine candidate' but does not specify its current development stage.
What does 'exclusive global rights' entail for the Licensee?
Exclusive global rights mean the Licensee has the sole right to develop, manufacture, and commercialize VAA437 worldwide.
What is the significance of this filing being a Form 6-K?
A Form 6-K is a report of foreign private issuers that provides information that the company has made or is required to make public in its home country, file with a stock exchange, or distribute to its security holders.
Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-09-26 12:45:29
Filing Documents
- ea0215074-6k_scinai.htm (6-K) — 10KB
- 0001213900-24-082106.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 26, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2